Advertisement


Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma and prior BTK inhibitor therapy. Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations (Abstract 7514).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Nirav N. Shah: So mantle cell lymphoma is a disease that sort of is felt to be a relapsing remitting disease, which means that most patients are going to relapse in their lifetime. Now, while we have very, very good therapies for relapse mantle cell, which generally include covalent BTK inhibitors. For those patients who progress after covalent BTK inhibitors, options are limited. We have treatments like CAR T-cell therapy, but not all patients are healthy enough, fit enough, or are in an area where CAR T-cell therapy is accessible. So pirtobrutinib was studied as part of the BRUIN trial to look specifically at patients with B-cell malignancies. And the data being reported is looking at the cohort of patients with mantle cell lymphoma who received this drug in a relapsed refractory setting. Unlike other BTK inhibitors pirtobrutinib is a non-covalent reversible inhibitor showing that it has a different mechanism of action than the BTK inhibitors that are currently being used in the second line setting. As part of the BRUIN study, whether or not you had prior BTK exposure was not an exclusion, and so actually the majority of patients who received pirtobrutinib, 90 of them, actually had prior BTK exposure, which is an unmet need in mantle cell lymphoma. Despite seeing a different BTK inhibitor, first, the overall response rate with pirtobrutinib was 58% in this heavily pretreated group, which is really just exciting to have another oral agent be effective in that patient population. Not only was it effective, but there were also durable responses. And so now in this sort of two year long term follow-up, we know that the median duration of response for those patients who were responding to therapy was 18 months, and the median overall survival was nearly 2 years. This data actually led to this drug now being FDA approved and in this clinical setting and available, and part of that is because the safety profile that's demonstrated in the BRUIN study in this patient population was actually quite favorable. The toxicities were low and the traditional BTK toxicities, things like atrial fibrillation, hypertension, and bleeding were actually seen at very low rates, such that may occur actually in a general patient population. In conclusion, I think that pirtobrutinib represents a novel mechanism of action in inhibiting the BTK pathway and allowing patients that have failed other covalent BTK inhibitors to continue receiving an oral medication that has now shown incredible efficacy, safety, and durability.

Related Videos

Myelodysplastic Syndromes
Supportive Care

Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept

Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety profile consistent with that in previous studies (Abstract 7016).

Breast Cancer

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Myelodysplastic Syndromes

Amer Methqal Zeidan, MBBS, MHS, on Myelodysplastic Syndromes: New Data From the IMerge Study of Imetelstat

Amer Methqal Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, discusses phase III findings on the first-in-class telomerase inhibitor imetelstat, which was given to patients with heavily transfusion-dependent non-del(5q) lower-risk myelodysplastic syndromes that are resistant to erythropoiesis-stimulating agents. Imetelstat resulted in a significant and sustained red blood cell (RBC) transfusion independence in 40% of these heavily transfused patients. The response was also durable and accompanied by an impressive median hemoglobin rise of 3.6 g/dL, and seen in patients with and without ring sideroblasts. Importantly, reduced variant allele frequency was observed in the most commonly mutated myeloid genes which correlated with duration of transfusion independence and hemoglobin rise, therefore suggesting a disease-modifying potential of this agent (Abstract 7004).

Breast Cancer

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles, discuss phase III study findings on ribociclib plus endocrine therapy as adjuvant treatment in patients with hormone receptor–positive, HER2-negative early breast cancer. When added to standard-of-care endocrine therapy, ribociclib improved invasive disease–free survival with a well-tolerated safety profile (Abstract LBA500).

Advertisement

Advertisement




Advertisement